16:42 , Apr 5, 2018 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
22:38 , Jul 20, 2017 |  BC Innovations  |  Finance

Sharpless edge for NCI

The National Cancer Institute is poised to enter a new phase, under the leadership of Norman (Ned) Sharpless, following the June 9 announcement by the White House of the president’s choice to fill the large...
07:00 , Aug 1, 2016 |  BioCentury  |  Emerging Company Profile

Faster than McDonald

IQuity Inc. is developing assays to diagnose autoimmune diseases as soon as symptoms appear based on differences in RNA expression of both coding and non-coding genes. The company's first test could help physicians confirm difficult...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Theranostics Health, Avant Diagnostics deal

Avant acquired fellow diagnostic company Theranostics Health for 25 million shares of Avant valued at $8 million based on Avant’s close of $0.32 on May 11, the day before the deal was announced. Theranostics markets...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Amarantus BioScience, Avant Diagnostics deal

Avant acquired Amarantus BioScience’s Amarantus Diagnostics Inc. subsidiary for 80 million shares of Avant stock valued at $25.6 million based on Avant’s close of $0.32 on May 11, the day before the deal closed. Amarantus...
07:00 , Apr 2, 2015 |  BC Innovations  |  Finance

Public Funding Notebook: Expanding access, limiting grants

Expanding access, limiting grants The push to expand access to funding for young and new investigators has led to new policies at two NIH agencies. In January, the National Institute of General Medical Sciences (NIGMS)...
08:00 , Nov 22, 2010 |  BioCentury  |  Product Development

HDL Rising, Again

Four years after the high profile failure of Pfizer Inc. 's torcetrapib caused a serious rethink about the prospects of inhibiting cholesteryl ester transfer protein , data from a Phase III safety study last week...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

Avastin bevacizumab: Development discontinued

Roche said it discontinued development of Avastin for adjuvant colorectal cancer after it missed the primary endpoints in 2 previously reported Phase III trials in the indication (see BioCentury, April 27, 2009 & Sept. 27,...
07:00 , Oct 4, 2010 |  BioCentury  |  Finance

3Q approvals

3Q approvals Company Approval Abraxis BioScience Inc. (NASDAQ:ABII)/ Otsuka Pharmaceutical Co. Ltd. (Tokyo:4768) Japan approves Abraxane nab-paclitaxel to treat breast cancer Allergan Inc. (NYSE:AGN) EC approves Ozurdex dexamethasone intravitreal implant to treat macular edema following...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Clinical News

Avastin bevacizumab: Phase III data

Top-line data from the Phase III AVANT trial in 3,451 patients who had undergone surgery for high-risk stage II and III colon cancer showed that Avastin plus FOLFOX or XELOX chemotherapy missed the primary endpoint...